Cargando…

Use of loteprednol for routine prophylaxis after photorefractive keratectomy

BACKGROUND: The purpose of this work is to report our experience using loteprednol 0.5% for routine prophylaxis after photorefractive keratectomy in an academic refractive surgery center. MATERIALS AND METHODS: Photorefractive keratectomy was performed on 579 eyes from 316 patients in this retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Mifflin, Mark D, Leishman, Lisa L, Christiansen, Steven M, Sikder, Shameema, Hsu, Maylon, Moshirfar, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346185/
https://www.ncbi.nlm.nih.gov/pubmed/22570546
http://dx.doi.org/10.2147/OPTH.S30282
_version_ 1782232190616076288
author Mifflin, Mark D
Leishman, Lisa L
Christiansen, Steven M
Sikder, Shameema
Hsu, Maylon
Moshirfar, Majid
author_facet Mifflin, Mark D
Leishman, Lisa L
Christiansen, Steven M
Sikder, Shameema
Hsu, Maylon
Moshirfar, Majid
author_sort Mifflin, Mark D
collection PubMed
description BACKGROUND: The purpose of this work is to report our experience using loteprednol 0.5% for routine prophylaxis after photorefractive keratectomy in an academic refractive surgery center. MATERIALS AND METHODS: Photorefractive keratectomy was performed on 579 eyes from 316 patients in this retrospective chart review of patients treated postoperatively with either fluorometholone 0.1% (273 eyes) or loteprednol 0.5% (306 eyes). Primary outcome measures at 6 months included uncorrected distance visual acuity, corrected distance visual acuity, and manifest refraction spherical equivalent. Secondary outcome measures were incidence of corneal haze and increased intraocular pressure. RESULTS: There were no statistically significant differences in preoperative characteristics between the two groups when comparing age, sex, best-corrected visual acuity, spherical equivalent, or keratometry. Both groups achieved excellent visual outcomes, with a mean uncorrected distance visual acuity (logMAR) of 0.004 ± 1.4 in the fluorometholone group and −0.028 ± 1.1 in the loteprednol group (P = 0.013) at 6 months. Postoperative corneal haze and increased intraocular pressure were uncommon and not statistically different between the groups. CONCLUSION: Loteprednol 0.5% performed similarly to fluorometholone 0.1% when used for prophylaxis following photorefractive keratectomy. The incidence of haze and increased intraocular pressure were similar between the two groups.
format Online
Article
Text
id pubmed-3346185
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33461852012-05-08 Use of loteprednol for routine prophylaxis after photorefractive keratectomy Mifflin, Mark D Leishman, Lisa L Christiansen, Steven M Sikder, Shameema Hsu, Maylon Moshirfar, Majid Clin Ophthalmol Original Research BACKGROUND: The purpose of this work is to report our experience using loteprednol 0.5% for routine prophylaxis after photorefractive keratectomy in an academic refractive surgery center. MATERIALS AND METHODS: Photorefractive keratectomy was performed on 579 eyes from 316 patients in this retrospective chart review of patients treated postoperatively with either fluorometholone 0.1% (273 eyes) or loteprednol 0.5% (306 eyes). Primary outcome measures at 6 months included uncorrected distance visual acuity, corrected distance visual acuity, and manifest refraction spherical equivalent. Secondary outcome measures were incidence of corneal haze and increased intraocular pressure. RESULTS: There were no statistically significant differences in preoperative characteristics between the two groups when comparing age, sex, best-corrected visual acuity, spherical equivalent, or keratometry. Both groups achieved excellent visual outcomes, with a mean uncorrected distance visual acuity (logMAR) of 0.004 ± 1.4 in the fluorometholone group and −0.028 ± 1.1 in the loteprednol group (P = 0.013) at 6 months. Postoperative corneal haze and increased intraocular pressure were uncommon and not statistically different between the groups. CONCLUSION: Loteprednol 0.5% performed similarly to fluorometholone 0.1% when used for prophylaxis following photorefractive keratectomy. The incidence of haze and increased intraocular pressure were similar between the two groups. Dove Medical Press 2012 2012-05-01 /pmc/articles/PMC3346185/ /pubmed/22570546 http://dx.doi.org/10.2147/OPTH.S30282 Text en © 2012 Mifflin et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Mifflin, Mark D
Leishman, Lisa L
Christiansen, Steven M
Sikder, Shameema
Hsu, Maylon
Moshirfar, Majid
Use of loteprednol for routine prophylaxis after photorefractive keratectomy
title Use of loteprednol for routine prophylaxis after photorefractive keratectomy
title_full Use of loteprednol for routine prophylaxis after photorefractive keratectomy
title_fullStr Use of loteprednol for routine prophylaxis after photorefractive keratectomy
title_full_unstemmed Use of loteprednol for routine prophylaxis after photorefractive keratectomy
title_short Use of loteprednol for routine prophylaxis after photorefractive keratectomy
title_sort use of loteprednol for routine prophylaxis after photorefractive keratectomy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346185/
https://www.ncbi.nlm.nih.gov/pubmed/22570546
http://dx.doi.org/10.2147/OPTH.S30282
work_keys_str_mv AT mifflinmarkd useofloteprednolforroutineprophylaxisafterphotorefractivekeratectomy
AT leishmanlisal useofloteprednolforroutineprophylaxisafterphotorefractivekeratectomy
AT christiansenstevenm useofloteprednolforroutineprophylaxisafterphotorefractivekeratectomy
AT sikdershameema useofloteprednolforroutineprophylaxisafterphotorefractivekeratectomy
AT hsumaylon useofloteprednolforroutineprophylaxisafterphotorefractivekeratectomy
AT moshirfarmajid useofloteprednolforroutineprophylaxisafterphotorefractivekeratectomy